By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Estrella Immunopharma, Inc. insiders have been one-way buyers this past year: one person put roughly $2,594 into the stock and nobody sold on the open market.
The largest purchase came from Xu Jiandong (CFO), about $1,330. That includes C-suite money, which tends to get the most attention.
On the institutional side, 15 funds reported holding ESLA at the end of Q2 2026, and more funds sold than bought. Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 2 of the last 7 full quarters.
Are insiders buying or selling ESLA stock?
In the last 12 months Estrella Immunopharma, Inc. insiders made open-market purchases worth about $2,594 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in ESLA?
The most recent open-market insider trade in ESLA was filed on 2026-04-29.
How many institutions own ESLA?
15 investment managers reported holding ESLA in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded ESLA?
No congressional trades in ESLA were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).